<DOC>
	<DOCNO>NCT00796003</DOCNO>
	<brief_summary>The purpose study determine recommend dose level JNJ-30979754 ( decitabine ) well assess safety effectiveness patient Myelodysplastic Syndrome ( MDS ) .</brief_summary>
	<brief_title>A Study JNJ-30979754 ( Decitabine ) Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>This open-label ( physician patient know name dosage drug ) , multi-center study . This study consist two part , Phase I Phase II . In Phase I , approximately 9 participant enrol ie , 3 participant dose level 1 ( 15 mg/m2 JNJ-30979754 ) 6 participant dose level 2 ( 20 mg/m2 JNJ-30979754 ) . Once tolerability 20 mg/m2 confirm additional 30 participant include receive 20 mg/m2 approximate total participant Phase II 36 . This study include screen period ( within 14 day prior day initial administration Cycle 1 ) dosing period ( 1 cycle consist administration study medication first 5 consecutive day + rest 23 day ; ie , total 28 day ) . Cycles reapeated participant decitabine expect effective . Safety evaluation include assessment adverse event , vital sign , body weight , clinical laboratory test : hematology , blood biochemistry urinalysis , cardiopulmonary function test : ECG , chest X ray oximeter analysis .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Myelodysplastic syndrome ( de novo secondary ) fit recognize FrenchAmericanBritish classification : refractory anemia , refractory anemia ring sideroblast , refractory anemia excess blast , refractory anemia excess blast transformation , chronic myelomonocytic leukemia white blood cell less 13,000 /mm3 International Prognostic Scoring System ( IPSS ) great equal 0.5 ( Intermediate1 , Intermediate2 high risk ) bone marrow assessment bone marrow cytogenetics within 28 day study registration 20 year old Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Normal renal hepatic function Acute Myeloid Leukemia ( AML ) bone marrow blast great equal 30 % Participants history highdose cytarabine ( AraC ) therapy ( great 1,000 mg/m2/day ) Participants administer adrenal cortex hormone anabolic hormone within 7 day study initiation Participants receive colony stimulate factor ( CSF ) formulation within 7 day study initiation Active double cancer Uncontrolled cardiac disease cognitive heart failure Uncontrolled restrictive obstructive pulmonary disease Uncontrolled diabetes mellitus Active viral bacterial infection Known positive serology Human immunodeficiency virus</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Decitabine</keyword>
	<keyword>JNJ-30979754</keyword>
</DOC>